Published phase 1 findings support the promising efficacy and tolerability of anito-cel in relapsed/refractory multiple myeloma, explains lead author Matthew Frigault, MD.
|Videos|January 16, 2017
Monoclonal Antibodies in Relapsed Multiple Myeloma with Cristina Gasparetto, MD: Case 2
Monoclonal Antibodies in Relapsed Multiple Myeloma with Cristina Gasparetto, MD
Advertisement
Case Scenario 2:
January 2015
- The patient is a 72-year old female who was diagnosed with ISS stage I multiple myeloma.
- She is an insulin dependent diabetic who is experiencing peripheral neuropathy.
- Her cytogenetics were classified as standard risk.
- Performance status 1.
- She received treatment with lenalidomide (25 mg daily) and low-dose dexamethasone with a good response.
- After a year she decided to come off of lenalidomide therapy.
July 2016
- Six months after stopping therapy, the patient had increasing fatigue and weakness.
- CT scan revealed several bone lesions.
- Patient was started on daratumumab, lenalidomide and dexamethasone
Advertisement
Related to this article
In the phase 3 EXCALIBER-RRMM trial, iberdomide plus daratumumab and dexamethasone doubled MRD-negative complete response rates over standard therapy in relapsed myeloma.
Closing sessions at IMS 2026 featured MRD-guided treatment strategies, real-world CAR T-cell data, and mixed results on cilta-cel neurotoxicity prevention in myeloma.
Etentamig significantly improved response and survival over standard therapy in the phase 3 CERVINO trial, headlining day 3 of IMS 2026 myeloma coverage.
In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
Half of patients who stopped MRD-guided maintenance in GEM2014MAIN remained progression-free at 7 years, as IMS 2026 also featured DREAMM-9, MIDAS, and novel bispecific data.
A new IMS/IMWG consensus definition requires 5 years of treatment-free, MRD-negative remission before multiple myeloma can be called cured.
Mezigdomide plus elranatamab yielded a 100% ORR in MELT-MM, as other IMS 2026 abstracts covered cevostamab, anito-cel vs cilta-cel, and linvoseltamab in HR-SMM.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Anito-Cel Delivers Durable Responses With Low Neurotoxicity in RRMM
2
Risk, Histology, and Metastatic Site Guide First-Line RCC Treatment Choices
3
FDA Application Withdrawn for I-DXd in Small Cell Lung Cancer
4
Frontline CAR T and Bispecific Antibodies Are the Next Frontier in Myeloma
5